Want to see IGC full AI Analyst Report?
IGC Stock Chart & Stats
$0.26
>-$0.01(-0.38%)
At close: 4:00 PM EDT
$0.26
>-$0.01(-0.38%)
Day’s Range― - ―
52-Week Range$0.24 - $0.50
Previous Close$0.27
Volume109.78K
Average Volume (3M)715.71K
Market Cap
$31.84M
Enterprise Value$26.51
Total Cash (Recent Filing)$354.00K
Total Debt (Recent Filing)$1.08M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Nov 18, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding103,384,010
10 Day Avg. Volume826,885
30 Day Avg. Volume715,709
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.08
Price to Sales (P/S)21.08
P/FCF Ratio-4.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.50Price Target Upside2015.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.09
Revenue Forecast (FY)$1.10M
Bulls Say, Bears Say
Bulls Say
Modest LeverageLow debt relative to equity limits near-term balance-sheet strain and gives IGC more financial flexibility than highly leveraged peers while it funds clinical development.
Executive Debt ConversionThe conversion reduced liabilities without a cash outlay and increased stockholders’ equity, providing durable balance-sheet support while management retained exposure to the company’s long-term outcome.
Continued Credit AccessMaintaining access to a substantial credit facility supports continued research, clinical, and operating activities, giving IGC funding flexibility while it remains pre-commercial.
Bears Say
Small, Declining RevenueLimited and declining revenue shows that IGC has not yet established meaningful commercial traction, leaving the business dependent on successful development and future commercialization of its drug candidates.
Severe Operating LossesLosses remain far out of proportion to revenue, indicating an unsustainable cost structure and no demonstrated path to breakeven without materially higher revenue or reduced development spending.
Persistent Cash BurnPersistent negative operating and free cash flow means IGC cannot currently fund its activities internally, increasing reliance on external financing and creating dilution or liquidity risk if development costs persist.
IGC Pharma News
IGC FAQ
What was IGC Pharma’s price range in the past 12 months?
IGC Pharma lowest stock price was $0.23 and its highest was $0.50 in the past 12 months.
What is IGC Pharma’s market cap?
IGC Pharma’s market cap is $31.84M.
When is IGC Pharma’s upcoming earnings report date?
IGC Pharma’s upcoming earnings report date is Nov 18, 2026 which is in 85 days.
How were IGC Pharma’s earnings last quarter?
IGC Pharma released its earnings results on Jun 15, 2026. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is IGC Pharma overvalued?
According to Wall Street analysts IGC Pharma’s price is currently Undervalued.
Does IGC Pharma pay dividends?
IGC Pharma does not currently pay dividends.
What is IGC Pharma’s EPS estimate?
IGC Pharma’s EPS estimate is -0.02.
How many shares outstanding does IGC Pharma have?
IGC Pharma has 103,384,010 shares outstanding.
What happened to IGC Pharma’s price movement after its last earnings report?
IGC Pharma reported an EPS of -$0.02 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of IGC Pharma?
Currently, no hedge funds are holding shares in IGC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IGC Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (2015.38% Upside)
$5.50 (2015.38% Upside)
Blogger Sentiment
Bullish
IGC Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.55%
Trailing 12-Months
Company Description
IGC Pharma
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
IGC Stock 12 Month Forecast
Average Price Target
$5.50
▲(2015.38% Upside)
Technical Analysis
Ownership Overview
12.65% Insiders
1.32% Mutual Funds
0.77% Other Institutional Investors
83.69% Public Companies and
Individual Investors